Monday, April 21, 2014

Roth starts AcelRx Pharma at buy

Roth starts AcelRx Pharma at buy

April 14, 2014 by · Leave a Comment 

Tweet Roth Capital Partners has initiated coverage of AcelRx Pharmaceuticals (NASDAQ:ACRX) with a “buy” rating and $22 price target. The stock closed at $10.32 on Friday. “We believe Zalviso is a disruptive technology that will transform the way many hospitals treat patients with moderate-to-severe acute pain, primarily in the postoperative setting, by providing a solution demonstrated to […]

Roth starts Flamel Technologies at buy

Roth starts Flamel Technologies at buy

April 11, 2014 by · Leave a Comment 

Tweet Roth Capital Partners has initiated coverage of Flamel Technologies (NASDAQ:FLML) with a “buy’ rating and $20 price target. The stock closed at $13.74 on Thursday. “The impetus for our buy rating is the potential for the company’s Eclat division to drive significant, and near-term, EPS profitability,” writes analyst Scott Henry. “The company’s longer-term pipeline […]

Roth ups Lion Biotechnologies target to $20

Roth ups Lion Biotechnologies target to $20

April 8, 2014 by · Leave a Comment 

Tweet Roth Capital Partners has raised its price target for “buy-rated” Lion Biotechnologies (OTC:LBIO) to $20 from $15, after Dr. Steven Rosenberg of the NCI presented Phase 2 data at the American Association of Cancer Research meeting from an ongoing Phase 2 study showing strong response rates from Lion’s tumor infiltrating lymphocyte (TIL) technology in […]

Roth starts Durata Therapeutics at buy

Roth starts Durata Therapeutics at buy

March 6, 2014 by · Leave a Comment 

Tweet Roth Capital Partners has initiated coverage of Durata Therapeutics (NASDAQ:DRTX) with a “buy” rating and $20 price target. The stock was quoted at $14.09 on Thursday afternoon. “We believe that Dalvance, a novel, once-weekly, two-dose antibiotic, is best positioned among new drug candidates to treat the rising threat of antibiotic resistance from ‘super bugs’, including […]

Roth reinitiates coverage of Cytokinetics at buy

Roth reinitiates coverage of Cytokinetics at buy

March 5, 2014 by · Leave a Comment 

Tweet Roth Capital Partners has reinitiated coverage of Cytokinetics (NASDAQ:CYTK) with a “buy” rating and $25 price target, saying a major catalyst is expected late April 2014, with Phase 2b data from the BENEFIT-ALS trial. The stock was quoted at $10.64, up 5.5%, on Wednesday afternoon. “We recommend investors own the stock ahead of this […]

Roth starts BioCryst at buy

Roth starts BioCryst at buy

January 21, 2014 by · Leave a Comment 

Tweet Roth Capital Partners has initiated coverage of BioCryst Pharmaceuticals (NASDAQ:BCRX) with a “buy” rating and price target of $18. The stock closed at $11.63 on Tuesday. “We think BioCryst is on its way to achieving its stated goal of dominating the hereditary angioedema (HAE) therapy market with the first and only once-daily pill for […]

Roth ups Chelsea Therapeutics price target

Roth ups Chelsea Therapeutics price target

January 17, 2014 by · Leave a Comment 

Tweet Roth Capital Partners has raised its price target for “buy-rated” Chelsea Therapeutics (NASDAQ:CHTP) to $7 from $4, reflecting a positive FDA panel ruling for its Northera drug candidate. The stock closed at $4.70 on Thursday. On Tuesday, the FDA’s Cardiovascular and Renal Drugs Advisory Committee (CRDAC) voted 16-1 to recommend approval of Northera for […]

Roth ups EnteroMedics price target

Roth ups EnteroMedics price target

December 4, 2013 by · Leave a Comment 

Tweet Roth Capital Partners has raised its price target for “buy-rated” EnteroMedics (NASDAQ:ETRM) to $3 from $2 after the company announced positive 18-month data for its ReCharge pivotal trial that demonstrated durable and safe ongoing weight loss. The stock closed at $2.24 on Tuesday. “We believe the company’s continued regulatory progress and positive 18-month data […]

Roth launches online investment platform

Roth launches online investment platform

October 29, 2013 by · Leave a Comment 

Tweet Roth Capital Partners has launched an online investment platform called OpenRound.com in order to simplify the “road show” for growth-stage companies and create access to accredited investors. In a statement, Roth said that by leveraging the power of the internet, accredited investors residing around the world can find, review, engage with and invest in […]

Roth ups Catalyst Pharma price target

Roth ups Catalyst Pharma price target

October 16, 2013 by · Leave a Comment 

Tweet Roth Capital Partners has raised its price target on “buy-rated” Catalyst Pharmaceutical Partners (NASDAQ:CPRX) to $3.75 from $2.75, after the company completed a recent financing and a data monitoring committee recommended that its Phase 3 Firdapse trial continue as planned. Shares of Catalyst Pharma closed at $2.70 on Tuesday. “This [price target] increase reflects […]

Next Page »

Google+